# GC Therapeutics

> GC Therapeutics is a Cambridge biotechnology company programming induced pluripotent stem cells with selected transcription factors instead of guiding them through long, bespoke differentiation protocols. Its TFome platform, Cell State Cookbook and predictive models are intended to make off-the-shelf cell medicines faster and more repeatable, starting with demyelinating neurological disease and type 1 diabetes. The promise is industrial cell production; the proof that matters next is safety and efficacy in people.

- **Founded:** 2019
- **Headquarters:** Cambridge, United States
- **Founders:** Parastoo Khoshakhlagh, Ph.D. (CEO and Co-Founder), Alex Ng, Ph.D. (Chief Innovation Officer and Co-Founder), George Church, Ph.D. (Co-Founder and Scientific Advisor), Cory Smith, Ph.D. (Scientific Co-Founder)
- **Team size:** Approximately 44-45 employees; LinkedIn listed 44 employees and an 11-50 company-size band in 2026.
- **Products:** TFome, SuperCells, Cell State Cookbook, Demyelinating disease program, Type 1 diabetes program
- **Notable:** Built a published library of 1,732 human transcription factors and variants for cell-fate engineering., Demonstrated rapid generation of multiple cell types, including neurons, oligodendrocytes, fibroblasts, endothelial cells and microglia-like cells., Published a six-factor method for generating microglia-like cells in Nature Communications in 2025.

## Products & services

- **TFome** — A cellular-programming platform built around a comprehensive library of human transcription factors, multidimensional screening, gene editing and predictive models to identify combinations that drive desired cell fates.
- **SuperCells** — GCTx's term for off-the-shelf iPSC-derived cells that are further engineered for disease-relevant potency, engraftment, immune compatibility or other functional traits.
- **Cell State Cookbook** — An empirical map of transcription-factor-driven transitions across more than 300 human cell states, built from more than two million tested combinations and used to train predictive cell-state models.
- **Demyelinating disease program** — A preclinical neurology program, including multiple sclerosis, intended to name a development candidate in 2026.
- **Type 1 diabetes program** — A discovery-stage regenerative cell-therapy effort aimed at a best-in-class approach for type 1 diabetes.

## Achievements

- Built a published library of 1,732 human transcription factors and variants for cell-fate engineering.
- Demonstrated rapid generation of multiple cell types, including neurons, oligodendrocytes, fibroblasts, endothelial cells and microglia-like cells.
- Published a six-factor method for generating microglia-like cells in Nature Communications in 2025.
- Raised $75 million in total capital, including a $65 million Series A in 2024.
- Completed a Cell State Cookbook spanning more than 300 human cell states and more than two million tested TF combinations.
- Won recognition from Massachusetts Life Sciences Innovation Day, Harvard's President's Innovation Challenge, YEi Start in France, Amgen and Biogen.

## Latest updates

- **2026-05** — Appointed former BlueRock Therapeutics CSO Stefan Irion as chief scientific officer; Alex Ng moved to chief innovation officer to focus on TFome, the Cell State Cookbook and virtual cell models.
- **2026-01** — Unveiled programs in demyelinating neurological disorders and type 1 diabetes, reported feedback from FDA and EMA, and appointed Kate Haviland board chair.
- **2025-06** — Published an iterative transcription-factor screen that generated microglia-like cells using a six-factor combination.
- **2025-04** — Added drug-development leader Kai-Hsin Chang and technical-operations leader Azadeh Golipour to prepare for translational and manufacturing work.
- **2024-09** — Publicly launched with a $65 million Series A and $75 million raised in total.

## Links

- Website: https://www.gc-tx.com/
- LinkedIn: https://www.linkedin.com/company/gctx/
- Twitter/X: https://x.com/GCTherapeutics

---

Profile page: https://yespress.io/gc-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-20